State Street’s Moleculin Biotech MBRX Stock Holding History

State Street’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-190	Closed	-$61.3K	–	4392
2023 Q4	$61.3K	Hold	190	–	–	﹤0.01%	4160
2023 Q3	$30.5K	Hold	190	–	–	﹤0.01%	4374
2023 Q2	$41.3K	Hold	190	–	–	﹤0.01%	4467
2023 Q1	$68.5K	Hold	190	–	–	﹤0.01%	4423
2022 Q4	$75.7K	Hold	190	–	–	﹤0.01%	4449
2022 Q3	$76K	Hold	190	–	–	﹤0.01%	4553
2022 Q2	$104K	Hold	190	–	–	﹤0.01%	4513
2022 Q1	$127K	Buy	190 +30	+19%	+$17.2K	﹤0.01%	4564
2021 Q4	$111K	Hold	160	–	–	﹤0.01%	4555
2021 Q3	$180K	Hold	160	–	–	﹤0.01%	4390
2021 Q2	$220K	Buy	+160	New	+$218K	﹤0.01%	4183

Other funds holding MBRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AWM

Atticus Wealth Management Palm Beach Gardens, Florida $420M AUM 23.31% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FIM

FWL Investment Management Dallas, Texas $456M AUM 60.63% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

State Street's MBRX Position: Q1 2024 in Review

State Street sold out of Moleculin Biotech (MBRX) in Q1 2024, closing a stake of 190 shares — an estimated $61.3K sold.

State Street first reported a position in MBRX in Q2 2021 and held it in 11 quarters. The position peaked at $220K in Q2 2021. 15 funds tracked by Wall St. Rank hold MBRX as of Q1 2024.

State Street reported no remaining Moleculin Biotech position as of Q1 2024 after selling out during the quarter.
State Street sold 190 Moleculin Biotech shares in Q1 2024, an estimated $61.3K.
State Street first reported a position in Moleculin Biotech in Q2 2021 and held it in 11 quarters.
State Street's Moleculin Biotech position peaked at $220K in Q2 2021.
15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2024.

Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.